Pancreatic Cancer: Epidemiology and Patient-Based Market Forecasts, Treatment Algorithm, and Marketed and Pipeline Drug Analysis

  • ID: 3797448
  • Drug Pipelines
  • 180 pages
  • Datamonitor Healthcare
1 of 3
The prognosis of patients with pancreatic cancer remains poor; however, this clinical need will drive future market expansion and the development of several targeted therapies.

This report addresses the following questions:

- What are the current treatment options for patients with pancreatic cancer in each therapeutic setting?
- Which products will drive growth of the pancreatic cancer market during 2015-24?
- Which brands will experience generic competition over the course of the forecast period and what impact will this have on the value of the overall pancreatic cancer market?
- How do pipeline therapies compare in terms of their clinical and commercial attractiveness, and how are companies attempting to differentiate their products?
- Which pipeline products will have a limited uptake in the pancreatic cancer market?
Note: Product cover images may vary from those shown
2 of 3
FORECAST: PANCREATIC CANCER

- Executive Summary
- Market Overview and Trends
- Market Definition and Methodology
- Abraxane (albumin-bound paclitaxel)
- Momelotinib
- Tarceva (erlotinib)
- Primary Research Methodology

TREATMENT: PANCREATIC CANCER

- Executive Summary
- Survey Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends

EPIDEMIOLOGY: PANCREATIC CANCER

- Executive Summary
- Sources and Methodology
- Forecast
- Epidemiologist Insight,
- Strengths and Limitations

MARKETED DRUGS: PANCREATIC CANCER

- Executive Summary
- Product Overview
- Product profile: Abraxane
- Product profile: Onivyde
- Product profile: TS-
- Product profile: Tarceva

PIPELINE: PANCREATIC CANCER

- Executive Summary
- Clinical Pipeline Overview
- Product profile (late stage): HyperAcute-Pancreas
- Product profile (late stage): Lynparza
- Product profile (late stage): Polyclonal Antibody Stimulator
- Product profile (late stage): Yttrium-
- clivatuzumab tetraxetan
- Product profile (late stage): masitinib
- Product profile (late stage): momelotinib
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll